24 results on '"Qayyum, Abbas Ali"'
Search Results
2. Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial.
- Author
-
Qayyum, Abbas Ali, van Klarenbosch, Bas, Frljak, Sabina, Cerar, Andraz, Poglajen, Gregor, Traxler‐Weidenauer, Denise, Nadrowski, Pawel, Paitazoglou, Christina, Vrtovec, Bojan, Bergmann, Martin W., Chamuleau, Steven A. J., Wojakowski, Wojtek, Gyöngyösi, Mariann, Kraaijeveld, Adriaan, Hansen, Kristian Schultz, Vrangbæk, Karsten, Jørgensen, Erik, Helqvist, Steffen, Joshi, Francis Richard, and Johansen, Ellen Mønsted
- Subjects
- *
BRAIN natriuretic factor , *STROMAL cells , *HEART failure , *VENTRICULAR ejection fraction , *ADIPOSE tissue diseases , *CARDIAC patients - Abstract
Aims: The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue‐derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischaemic heart failure with reduced ejection fraction (HFrEF). Methods and results: The study was a European multicentre, double‐blind, placebo‐controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were New York Heart Association (NYHA) class II–III, left ventricular ejection fraction (LVEF) <45%, and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) levels >300 pg/ml. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. The primary endpoint was change in left ventricular end‐systolic volume (LVESV) at 6‐month follow‐up measured by echocardiography. A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug‐related severe adverse events or difference in cardiac‐related adverse events during a 3‐year follow‐up period. There were no significant differences between groups during follow‐up in LVESV (0.3 ± 5.0 ml, p = 0.945), nor in secondary endpoints of left ventricular end‐diastolic volume (−2.0 ± 6.0 ml, p = 0.736) and LVEF (−1.6 ± 1.0%, p = 0.119). The NYHA class improved slightly within the first year in both groups without any difference between groups. There were no changes in 6‐min walk test, NT‐proBNP, C‐reactive protein or quality of life the first year in any groups. Conclusion: The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre‐defined endpoints and induce restoration of cardiac function or clinical symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.
- Author
-
Qayyum, Abbas Ali, Mouridsen, Mette, Nilsson, Brian, Gustafsson, Ida, Schou, Morten, Nielsen, Olav Wendelboe, Hove, Jens Dahlgaard, Mathiasen, Anders Bruun, Jørgensen, Erik, Helqvist, Steffen, Joshi, Francis Richard, Johansen, Ellen Mønsted, Follin, Bjarke, Juhl, Morten, Højgaard, Lisbeth Drozd, Haack‐Sørensen, Mandana, Ekblond, Annette, and Kastrup, Jens
- Subjects
HEART failure ,HEART failure patients ,STROMAL cells ,ADIPOSE tissues ,VENTRICULAR ejection fraction ,FAT cells - Abstract
Aims: Patients suffering from chronic ischaemic heart failure with reduced left ventricular ejection fraction (HFrEF) have reduced quality‐of‐life, repetitive hospital admissions, and reduced life expectancy. Allogeneic cell therapy is currently investigated as a potential treatment option after initially encouraging results from clinical autologous and allogeneic trials in patients with HFrEF. We aimed to investigate the allogeneic Cardiology Stem Cell Centre Adipose tissue derived mesenchymal Stromal Cell product (CSCC_ASC) as an add‐on therapy in patients with chronic HFrEF. Methods and results: This is a Danish multi‐centre double‐blinded placebo‐controlled phase II study with direct intra‐myocardial injections of allogeneic CSCC_ASC. A total of 81 HFrEF patients were included and randomized 2:1 to CSCC_ASC or placebo injections. The inclusion criteria were reduced left ventricular ejection fraction (LVEF ≤ 45%), New York Heart Association (NYHA) class II‐III despite optimal anti‐congestive heart failure medication and no further revascularization options. Injections of 0.3 mL CSCC_ASC (total cell dose 100 × 106 ASCs) (n = 54) or isotonic saline (n = 27) were performed into the viable myocardium in the border zone of infarcted tissue using the NOGA Myostar® catheter (Biological Delivery System, Cordis, Johnson & Johnson, USA). The primary endpoint, left ventricular end systolic volume (LVESV), was evaluated at 6‐month follow‐up. The safety was measured during a 3‐years follow‐up period. Results: Mean age was 67.0 ± 9.0 years and 66.6 ± 8.1 years in the ASC and placebo groups, respectively. LVESV was unchanged from baseline to 6‐month follow‐up in the ASC (125.7 ± 68.8 mL and 126.3 ± 72.5 mL, P = 0.827) and placebo (134.6 ± 45.8 mL and 135.3 ± 49.6 mL, P = 0.855) group without any differences between the groups (0.0 mL (95% CI −9.1 to 9.0 mL, P = 0.992). Neither were there significant changes in left ventricular end diastolic volume or LVEF within the two groups or between groups −5.7 mL (95% CI −16.7 to 5.3 mL, P = 0.306) and −1.7% (95% CI −4.4. to 1.0, P = 0.212), respectively). NYHA classification and 6‐min walk test did not alter significantly in the two groups (P > 0.05). The quality‐of‐life, total symptom, and overall summary score improved significantly only in the ASC group but not between groups. There were 24 serious adverse events (SAEs) in the ASC group and 11 SAEs in the placebo group without any significant differences between the two groups at 1‐year follow‐up. Kaplan–Meier plot using log‐rank test of combined cardiac events showed an overall mean time to event of 30 ± 2 months in the ASC group and 29 ± 2 months in the placebo group without any differences between the groups during the 3 years follow‐up period (P = 0.994). Conclusions: Intramyocardial CSCC_ASC injections in patients with chronic HFrEF were safe but did not improve myocardial function or structure, nor clinical symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Semi‐quantitative myocardial perfusion measured by computed tomography in patients with refractory angina: a head‐to‐head comparison with quantitative rubidium‐82 positron emission tomography as reference
- Author
-
Qayyum, Abbas Ali, Kühl, Jørgen Tobias, Kjaer, Andreas, Hasbak, Philip, Kofoed, Klaus Fuglsang, and Kastrup, Jens
- Published
- 2017
- Full Text
- View/download PDF
5. Stem Cell Therapy to Treat Heart Ischaemia: Implications for Diabetes Cardiovascular Complications
- Author
-
Qayyum, Abbas Ali, Mathiasen, Anders Bruun, and Kastrup, Jens
- Published
- 2014
- Full Text
- View/download PDF
6. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)
- Author
-
Mathiasen, Anders Bruun, Qayyum, Abbas Ali, Jørgensen, Erik, Helqvist, Steffen, Fischer-Nielsen, Anne, Kofoed, Klaus F., Haack-Sørensen, Mandana, Ekblond, Annette, and Kastrup, Jens
- Published
- 2015
- Full Text
- View/download PDF
7. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)
- Author
-
Mathiasen, Anders Bruun, Jørgensen, Erik, Qayyum, Abbas Ali, Haack-Sørensen, Mandana, Ekblond, Annette, and Kastrup, Jens
- Published
- 2012
- Full Text
- View/download PDF
8. Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design
- Author
-
Qayyum, Abbas Ali, Haack-Sørensen, Mandana, Mathiasen, Anders Bruun, Jørgensen, Erik, Ekblond, Annette, and Kastrup, Jens
- Published
- 2012
- Full Text
- View/download PDF
9. In Vivo MRI Tracking of Mesenchymal Stromal Cells Labeled with Ultrasmall Paramagnetic Iron Oxide Particles after Intramyocardial Transplantation in Patients with Chronic Ischemic Heart Disease.
- Author
-
Mathiasen, Anders Bruun, Qayyum, Abbas Ali, Jørgensen, Erik, Helqvist, Steffen, Ekblond, Annette, Ng, Michael, Bhakoo, Kishore, and Kastrup, Jens
- Subjects
- *
IRON oxides , *CORONARY disease , *FERRIC oxide , *STROMAL cells , *INTRA-aortic balloon counterpulsation , *IRON oxide nanoparticles , *STEM cell treatment - Abstract
Background. While regenerative stem cell therapy for ischemic heart disease has moved into phase 3 studies, little is still known about retention and migration of cell posttransplantation. In human studies, the ability to track transplanted cells has been limited to labeling with radioisotopes and tracking using nuclear imaging. This method is limited by low resolution and short half-lives of available radioisotopes. Longitudinal tracking using magnetic resonance imaging (MRI) of myocardial injected cells labeled with iron oxide nanoparticles has shown promising results in numerous preclinical studies but has yet to be evaluated in human studies. We aimed to evaluate MRI tracking of mesenchymal stromal cells (MSCs) labeled with ultrasmall paramagnetic iron oxide (USPIO) nanoparticles after intramyocardial transplantation in patients with ischemic heart disease (IHD). Methods. Five no-option patients with chronic symptomatic IHD underwent NOGA-guided intramyocardial transplantation of USPIO-labeled MSCs. Serial MRI scans were performed to track labeled cells both visually and using semiautomated T2∗ relaxation time analysis. For safety, we followed symptoms, quality of life, and myocardial function for 6 months. Results. USPIO-labeled MSCs were tracked for up to 14 days after transplantation at injection sites both visually and using semiautomated regional T2∗ relaxation time analysis. Labeling of MSCs did not impair long-term safety of treatment. Conclusion. This was a first-in-man clinical experience aimed at evaluating the utility of MRI tracking of USPIO-labeled bone marrow-derived autologous MSCs after intramyocardial injection in patients with chronic IHD. The treatment was safe, and cells were detectable at injection sites up to 14 days after transplantation. Further studies are needed to clarify if MSCs migrate out of the injection area into other areas of the myocardium or if injected cells are washed out into the peripheral circulation. The trial is registered with ClinicalTrials.gov NCT03651791. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study.
- Author
-
Qayyum, Abbas Ali, Mathiasen, Anders Bruun, Mygind, Naja Dam, Kühl, Jørgen Tobias, Jørgensen, Erik, Helqvist, Steffen, Elberg, Jens Jørgen, Kofoed, Klaus Fuglsang, Vejlstrup, Niels Groove, Fischer-Nielsen, Anne, Haack-Sørensen, Mandana, Ekblond, Annette, and Kastrup, Jens
- Subjects
- *
CORONARY heart disease treatment , *STROMAL cells , *VENTRICULAR ejection fraction , *EXERCISE physiology , *CLINICAL trials - Abstract
We aimed to evaluate the effect of intramyocardial injections of autologous VEGF-A165-stimulated adipose-derived stromal cells (ASCs) in patients with refractory angina. MyStromalCell trial is a randomized double-blind placebo-controlled study including sixty patients with CCS/NYHA class II-III, left ventricular ejection fraction > 40%, and at least one significant coronary artery stenosis. Patients were treated with ASC or placebo in a 2 : 1 ratio. ASCs from the abdomen were culture expanded and stimulated with VEGF-A165. At 6 months follow-up, bicycle exercise tolerance increased significantly in time duration 22 s (95%CI −164 to 208 s) (P=0.034), in watt 4 (95%CI −33 to 41, 0.048), and in METs 0.2 (95%CI −1.4 to 1.8) (P=0.048) in the ASC group while there was a nonsignificant increase in the placebo group in time duration 9 s (95%CI −203 to 221 s) (P=0.053), in watt 7 (95%CI −40 to 54) (P=0.41), and in METs 0.1 (95%CI −1.7 to 1.9) (P=0.757). The difference between the groups was not significant (P=0.680, P=0.608, and P=0.720 for time duration, watt, and METs, resp.). Intramyocardial delivered VEGF-A165-stimulated ASC treatment was safe but did not improve exercise capacity compared to placebo. However, exercise capacity increased in the ASC but not in the placebo group. This trial is registered with ClinicalTrials.gov
NCT01449032 . [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Influence of patient related factors on number of mesenchymal stromal cells reached after in vitro culture expansion for clinical treatment.
- Author
-
Qayyum, Abbas Ali, Kaur, Kamal Preet, Mathiasen, Anders Bruun, Haack-Sørensen, Mandana, Ekblond, Annette, and Kastrup, Jens
- Subjects
- *
CELLULAR therapy , *CARDIAC patients , *HEART diseases , *THERAPEUTICS , *STROMAL cells , *BODY mass index , *STEM cell transplantation , *CELL culture , *CELL physiology , *CHOLESTEROL , *CONNECTIVE tissue cells , *PHENOTYPES , *CYTOMETRY , *STROKE volume (Cardiac output) - Abstract
Background: Number of stromal cells injected in patients with ischaemic heart disease (IHD) may be of importance for the treatment efficacy, which in turn may be influenced by various patient-related factors. In this study, we investigate whether patient-related factors influence the number of autologous stromal cells reached after in vitro culture expansion for clinical therapy.Methods: Culture expansion data from 111 patients with IHD treated with autologous stromal cells in three clinical trials were used. We correlated the final cell count after two passages of cultivation with different patient factors.Results: There was a significant relation between body mass index (BMI) and the number of adipose derived stromal cells (ASCs) reached after culture expansion and for all patients included into the three studies (r = 0.375, p = .019 and r = 0.200, p = .036, respectively). Moreover, there was a significantly higher number of ASCs reached in patients with hypertension compared to those without hypertension and for all patients overall (68.8 ± 39.6 × 106 vs. 39.1 ± 23.6 × 106, p = .020 and 62.0 ± 55.0 × 106 vs. 29.0 ± 19.3 × 106, p < .001, respectively). The same tendency was seen with bone marrow derived mesenchymal stromal cells (MSCs) in patients with hypertension compared to those without hypertension (58.4 ± 61.8 × 106 vs. 22.6 ± 13.3 × 106, p < .001) and in males compared to females (56.4 ± 61.5 × 106 vs. 30.9 ± 27.9 × 106, p = .041). Moreover, a significant negative correlation between left ventricular ejection fraction and number of MSCs was found (r = -0.287, p = .017).Conclusions: Patient related factors such as BMI, hypertension and gender may influence the number of MSCs reached after in vitro culture expansion. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study.
- Author
-
Kastrup, Jens, Schou, Morten, Gustafsson, Ida, Nielsen, Olav W., Møgelvang, Rasmus, Kofoed, Klaus F., Kragelund, Charlotte, Hove, Jens Dahlgaard, Fabricius-Bjerre, Andreas, Heitman, Merete, Haack-Sørensen, Mandana, Lund, Lisbeth Drozd, Johansen, Ellen Mønsted, Qayyum, Abbas Ali, Mathiasen, Anders Bruun, and Ekblond, Annette
- Subjects
CORONARY heart disease treatment ,HEART failure treatment ,STEM cells ,PLACEBOS ,HOMOGRAFTS - Abstract
Background. Ischemic heart failure (IHF) has a poor prognosis in spite of optimal therapy. We have established a new allogeneic Cardiology Stem Cell Centre adipose-derived stromal cell (CSCC_ASC) product from healthy donors. It is produced without animal products, in closed bioreactor systems and cryopreserved as an off-the-shelf product ready to use. Study Design. A multicentre, double-blind, placebo-controlled phase II study with direct intramyocardial injections of allogeneic CSCC_ASC in patients with chronic IHF. A total of 81 patients will be randomised at 2 : 1 to CSCC_ASC or placebo. There is no HLA tissue type matching needed between the patients and the donors. Methods. The treatment will be delivered by direct injections into the myocardium. The primary endpoint is change in the left ventricle endsystolic volume at 6-month follow-up. Secondary endpoints are safety and changes in left ventricle ejection fraction, myocardial mass, stroke volume, and cardiac output. Other secondary endpoints are change in clinical symptoms, 6-minute walking test, and the quality of life after 6 and 12 months. Conclusion. The aim of the present study is to demonstrate safety and the regenerative efficacy of the allogeneic CSCC_ASC product from healthy donors in a double-blind, placebo-controlled, multicentre study in patients with IHF. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study.
- Author
-
Mygind, Naja Dam, Michelsen, Marie Mide, Pena, Adam, Qayyum, Abbas Ali, Frestad, Daria, Christensen, Thomas Emil, Ghotbi, Adam Ali, Dose, Nynne, Faber, Rebekka, Vejlstrup, Niels, Hasbak, Philip, Kjaer, Andreas, Prescott, Eva, and Kastrup, Jens
- Subjects
CORONARY artery physiology ,DIAGNOSIS ,CORONARY disease ,MYOCARDIUM physiology ,CARDIOMYOPATHIES ,ANALYSIS of variance ,ANGINA pectoris ,BLOOD circulation ,CARDIOLOGY ,DIAGNOSTIC imaging ,ECHOCARDIOGRAPHY ,CARDIAC patients ,MAGNETIC resonance imaging ,EVALUATION of medical care ,RESEARCH funding ,POSITRON emission tomography ,FIBROSIS ,DESCRIPTIVE statistics ,CORONARY angiography ,DISEASE complications - Abstract
Background: Even in absence of obstructive coronary artery disease women with angina pectoris have a poor prognosis possibly due to coronary microvascular disease. Coronary microvascular disease can be assessed by transthoracic Doppler echocardiography measuring coronary flow velocity reserve (CFVR) and by positron emission tomography measuring myocardial blood flow reserve (MBFR). Diffuse myocardial fibrosis can be assessed by cardiovascular magnetic resonance (CMR) T1 mapping. We hypothesized that coronary microvascular disease is associated with diffuse myocardial fibrosis. Methods: Women with angina, a clinically indicated coronary angiogram with <50 % stenosis and no diabetes were included. CFVR was measured using dipyridamole (0.84 mg/kg) and MBFR using adenosine (0.84 mg/kg). Focal fibrosis was assessed by 1.5 T CMR late gadolinium enhancement (0.1 mmol/kg) and diffuse myocardial fibrosis by T1 mapping using a modified Look-Locker pulse sequence measuring T1 and extracellular volume fraction (ECV). Results: CFVR and CMR were performed in 64 women, mean (SD) age 62.5 (8.3) years. MBFR was performed in a subgroup of 54 (84 %) of these women. Mean native T1 was 1023 (86) and ECV (%) was 33.7 (3.5); none had focal fibrosis. Median (IQR) CFVR was 2.3 (1.9; 2.7), 23 (36 %) had CFVR < 2 indicating coronary microvascular disease, and median MBFR was 2.7 (2.2; 3.0) and 19 (35 %) had a MBFR value below 2.5. No significant correlations were found between CFVR and ECV or native T1 (R² = 0.02 ; p = 0.27 and R² = 0.004; p = 0.61, respectively). There were also no correlations between MBFR and ECV or native T1 (R² = 0.1 ; p = 0.13 and R² = 0.004, p = 0.64, respectively). CFVR and MBFR were correlated to hypertension and heart rate. Conclusion: In women with angina and no obstructive coronary artery disease we found no association between measures of coronary microvascular disease and myocardial fibrosis, suggesting that myocardial ischemia induced by coronary microvascular disease does not elicit myocardial fibrosis in this population. The examined parameters seem to provide independent information about myocardial and coronary disease. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Mesenchymal stromal cell therapy in ischemic heart disease.
- Author
-
Kastrup, Jens, Mygind, Naja Dam, Qayyum, Abbas Ali, Mathiasen, Anders Bruun, Haack-Sørensen, Mandana, and Ekblond, Annette
- Subjects
CELLULAR therapy ,CORONARY heart disease treatment ,MESENCHYMAL stem cells ,STEM cell treatment ,HEART failure ,HEART cells - Abstract
Although, treatment of ischemic heart disease (IHD) has improved considerably within the last decades, it is still the main cause of death worldwide. Despite maximum treatment, many IHD patients suffer from refractory angina and heart failure, which severely limits their daily lives. Moreover, IHD is very costly for the health care system. Therefore, new treatment options and strategies are being researched intensely. Stem cell therapy to improve myocardial perfusion and stimulate growth of new cardiomyocytes could be a new way to go. Nevertheless, the results from clinical studies have varied considerably, probably due to the use of many different cell lines obtained from different tissues and the different patient populations. The present review will focus on treatment with the mesenchymal stromal cell from bone marrow and adipose tissue in animal and patients with acute and chronic IHD (CIHD). [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Coronary artery stent mimicking intracardiac thrombus on cardiac magnetic resonance imaging due to signal loss: case report
- Author
-
Qayyum, Abbas Ali, Vejlstrup, Niels Grove, Ahtarovski, Kiril Aleksov, Kofoed, Klaus Fuglsang, and Kastrup, Jens
- Subjects
- *
CORONARY disease , *DIAGNOSIS , *CARDIAC magnetic resonance imaging , *CARDIAC surgery , *SIGNAL processing , *SURGICAL stents , *CONTRAST media , *TOMOGRAPHY - Abstract
Abstract: Since the introduction of percutaneous coronary intervention for coronary artery disease, thousands of patients have been treated with the implantation of coronary stents. Moreover, several of the patients with coronary stent undergo cardiac magnetic resonance (CMR) imaging every year. This case report is of a 77-year-old man who was previously treated with the implantation of a coronary stent in the left circumflex artery. He underwent CMR imaging, which revealed a process 14×21 mm in the left atrium. Cardiac contrast computed tomography did not demonstrate any cardiac pathology. While the signal loss on MRI associated with implanted metallic devices is known, we report a case where an implanted coronary stent in the left circumflex artery led to an intracardiac signal loss mimicking intracardiac thrombus/tumor. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
16. Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review.
- Author
-
Hoeeg, Cecilie, Frljak, Sabina, Qayyum, Abbas Ali, Vrtovec, Bojan, Kastrup, Jens, Ekblond, Annette, and Follin, Bjarke
- Subjects
MESENCHYMAL stem cells ,DILATED cardiomyopathy ,PROTEIN expression ,HEART failure ,CRIME & the press - Abstract
Non-ischemic dilated cardiomyopathy (NIDCM) constitutes one of the most common causes to non-ischemic heart failure. Despite treatment, the disease often progresses, causing severe morbidity and mortality, making novel treatment strategies necessary. Due to the regenerative actions of mesenchymal stem cells (MSCs), they have been proposed as a treatment for NIDCM. This systematic review aims to evaluate efficacy and mode of action (MoA) of MSC-based therapies in NIDCM. A systematic literature search was conducted in Medline (Pubmed) and Embase. A total of 27 studies were included (3 clinical trials and 24 preclinical studies). MSCs from different tissues and routes of delivery were reported, with bone marrow-derived MSCs and direct intramyocardial injections being the most frequent. All included clinical trials and 22 preclinical trials reported an improvement in cardiac function following MSC treatment. Furthermore, preclinical studies demonstrated alterations in tissue structure, gene, and protein expression patterns, primarily related to fibrosis and angiogenesis. Consequently, MSC treatment can improve cardiac function in NIDCM patients. The MoA underlying this effect involves anti-fibrosis, angiogenesis, immunomodulation, and anti-apoptosis, though these processes seem to be interdependent. These encouraging results calls for larger confirmatory clinical studies, as well as preclinical studies utilizing unbiased investigation of the potential MoA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. ADIPOSE DERIVED STROMAL CELLS FOR REFRACTORY ANGINA: RESULTS FROM MYSTROMALCELL TRIAL.
- Author
-
Qayyum, Abbas Ali, Mathiasen, Anders, Mygind, Naja, Kuhl, Tobias, Joergensen, Erik, Helqvist, Steffen, Elberg, Jens Jørgen, Kofoed, Klaus, Vejlstrup, Niels, Fischer-Nielsen, Anne, Haack-Sørensen, Mandana, Ekblond, Annette, and Kastrup, Jens
- Subjects
- *
STROMAL cells , *ANGINA pectoris - Published
- 2017
- Full Text
- View/download PDF
18. Mesenchymal stromal cells to treat patients with non-ischaemic heart failure: Results from SCIENCE II pilot study.
- Author
-
Qayyum AA, Frljak S, Juhl M, Poglajen G, Zemljičl G, Cerar A, Litman T, Ekblond A, Haack-Sørensen M, Højgaard LD, Kastrup J, and Vrtovec B
- Abstract
Aims: Allogeneic stem cell therapy is more logistically suitable compared with autologous cell therapy for large-scale patient treatment. We aim to investigate the clinical safety and efficacy profile of the allogeneic adipose tissue derived mesenchymal stromal cell product (CSCC_ASC) as an add-on therapy in patients with chronic non-ischaemic heart failure with reduced left ventricular ejection fraction (HFrEF) < 40%., Methods and Results: This is a single-centre investigator-initiated randomized phase I/II study with direct intra-myocardial injections of 100 million allogeneic CSCC_ASC. A total of 30 HFrEF patients with New York Heart Association (NYHA) class ≥II despite optimal anticongestive heart failure medication and plasma NT-proBNP > 300 pg/mL (>35 pmol/L) were included and randomized 2:1 to CSCC_ASC or standard care. The primary endpoint left ventricular end systolic volume (LVESV) and other echo related parameters were analysed by an investigator blinded for treatment allocation. No difference in serious adverse events was observed between groups. LVESV decreased significantly from baseline to 6 months follow-up in the ASC group (153.7 ± 53.2 mL and 128.7 ± 45.6 mL, P < 0.001) and remained unchanged in the standard care group (180.4 ± 39.4 mL and 186.7 ± 48.9 mL, P = 0.652). There was a significant difference between the groups in LVESV change (31.3 ± 11.0 mL, P = 0.009). The difference from baseline to follow-up between the two groups in left ventricular end diastolic volume (LVEDV) was 18.7 ± 12.4 mL, P = 0.146 and in left ventricular ejection fraction (LVEF) -7.8 ± 2.1%, P = 0.001. Considering the baseline values of LVESV, LVEDV and LVEF as covariates, the difference between groups for change from baseline to follow-up resulted in a P-value of 0.056, 0.076, and 0.738, respectively. NYHA class and self-reported health did also improve significantly in the ASC group compared with the standard care group (0.7 ± 0.2, P = 0.001 and -12.8 ± 5.3, P = 0.025; respectively). There was no difference in NT-proBNP (-371 ± 455 pmol/L, P = 0.422) or in 6 min walk test (12 ± 31 m, P = 0.695) between groups., Conclusions: Intramyocardial injections of allogeneic CSCC_ASC in patients with chronic non-ischaemic HFrEF was safe and improved LVESV, LVEF, NYHA class, and self-reported health compared with standard care group., (© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
19. Multiple spontaneous isolated arterial dissections: a rare case report.
- Author
-
Tuffley RH and Qayyum AA
- Abstract
Spontaneous dissections in multiple arteries are a rare condition with clinical presentation varying from asymptomatic conditions to sudden death. We present a rare case where a routine thoracic computed tomography (CT) scan showed a type B aortic dissection. Medical records showed that the patient previously had been diagnosed with bilateral spontaneous isolated internal carotid artery dissections, which caused an attack of amaurosis fugax a few months earlier. The patient was asymptomatic during the admission with type B aortic dissection. However, the patient had a high blood pressure which was medically treated. A new CT scan confirmed earlier findings and revealed a spontaneous isolated dissection in the superior mesenteric artery. No progression was seen when the scan was compared to a new CT scan performed 10 days later. The type B aortic dissection was considered to be chronic and stable with no need for vascular intervention. This case report illustrates a rare condition of four isolated arterial dissections. The present case demonstrates the necessity of further examinations, which should be considered carefully when a patient presents with several independent arterial dissections., Competing Interests: None., (AJTR Copyright © 2024.)
- Published
- 2024
20. Giant Coronary Artery Aneurysm Due to Implantation of Drug-Eluting Stent.
- Author
-
Amir A and Qayyum AA
- Abstract
Development of coronary artery aneurysm after implantation of a drug-eluting stent is a rare complication. The mechanism behind aneurysm formation is unknown, but studies suggest hypersensitivity and inflammatory reactions elicited by the stent polymer. Here, we report a case of a 57-year-old man who was treated with a sirolimus-eluting Cypher
TM stent in the left anterior descending artery due to stable angina pectoris and left circumflex artery due to dissection. Coronary aneurysm formation at the site of stent implantation was discovered three years after the stents were deployed, and progression of the aneurysms was seen in the coronary artery angiography. We hypothesize about the mechanism of aneurysm formation and present management of the aneurysms., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Amir et al.)- Published
- 2024
- Full Text
- View/download PDF
21. Review of Randomized Controlled Trials in Patients with Peripartum Cardiomyopathy.
- Author
-
Mujkanovic J and Qayyum AA
- Subjects
- Pregnancy, Humans, Female, Bromocriptine therapeutic use, Bromocriptine pharmacology, Stroke Volume, Ventricular Function, Left, Prospective Studies, Peripartum Period, Randomized Controlled Trials as Topic, Cardiotonic Agents pharmacology, Cardiomyopathies drug therapy, Cardiomyopathies diagnosis, Heart Failure drug therapy, Pregnancy Complications, Cardiovascular drug therapy
- Abstract
Introduction: Peripartum cardiomyopathy (PPCM) is a rare but potentially lifethreatening disease, defined as idiopathic cardiomyopathy occurring towards the end of pregnancy or in the months following delivery, abortion or miscarriage. We aim to raise awareness of this condition and give an overview of current knowledge as well as an insight and comparison of clinical trials focusing on randomized controlled trials., Material and Methods: Systematic literature searches were conducted using PubMed up to December 2021. Studies published involving clinical trials and interventions in women with PPCM after 1970 were selected., Results: Randomized controlled trials have shown that the addition of Bromocriptine to standardized heart failure therapy improves outcome in terms of recovery of Left Ventricular Ejection Fraction (LVEF), symptoms and death. Bromocriptine 2.5 mg twice daily for two weeks followed by 2.5 mg once daily for six weeks had the best trend and outcome. The addition of Levosimendan to standardized heart failure therapy had no effect, whereas the addition of Selenium improved heart failure symptoms but did not reduce risk in terms of unrecovered LVEF or death. One prospective study showed potential usage of TNF-alfa inhibitors, but was never tried in a randomized clinical trial., Conclusion: PPCM is a rare and potentially fatal disease. New insights on pathophysiology, genetics and clinical studies, particularly randomized controlled trials, have shown that the addition of Bromocriptine has a beneficial effect in terms of improved LVEF and death. However, some clinical studies have shown promising results using anti-inflammatory pharmacological agents with an improvement in LVEF. We suggest that targeting an anti-inflammatory route may prove beneficial in patients with PPCM. However, further research is highly warranted., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2023
- Full Text
- View/download PDF
22. Cardiac Magnetic Resonance Imaging used for Evaluation of Adipose-Derived Stromal Cell Therapy in Patients with Chronic Ischemic Heart Disease.
- Author
-
Qayyum AA, Mathiasen AB, Mygind ND, Vejlstrup NG, and Kastrup J
- Subjects
- Aged, Chronic Disease, Female, Humans, Male, Middle Aged, Adipose Tissue metabolism, Magnetic Resonance Imaging, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells metabolism, Myocardial Ischemia diagnostic imaging, Myocardial Ischemia metabolism, Myocardial Ischemia physiopathology, Myocardial Ischemia therapy
- Abstract
Adipose-derived stromal cell (ASC) therapy is currently investigated as a new treatment option for patients with ischemic heart disease (IHD). The aim of this study was to evaluate the effect of ASC therapy in patients with chronic IHD measuring myocardial perfusion and cardiac function using cardiac magnetic resonance imaging (CMRI). Patients were included in MyStromalCell trial, a phase II, randomized, double-blinded, placebo-controlled study investigated the effect of ASCs in patients with chronic IHD with preserved left ventricular ejection fraction (LVEF). In total, 41 of 60 patients underwent cine, late enhancement, rest and stress imaging with CMRI. There was a non-significant difference between stress and rest values in maximal signal intensity, a measure of myocardial perfusion, from baseline to follow-up comparing placebo with ASC group (-52.52 ± 88.61 and 3.05 ± 63.17, p = 0.061, respectively). LVEF, myocardial mass, stroke volume, left ventricle end-diastolic volume and end-systolic volume changed non-significantly (-0.5 ± 4.7%, -3.5 ± 13.1 g, -0.7 ± 8.6 mL, 1.9 ± 25.1 mL and 2.6 ± 16.5 mL, respectively) in the placebo group and in the ASC group (0.7 ± 8.6%, 0.9 ± 10.8 g, -0.3 ± 26.1 mL, -3.0 ± 31.5 mL and -2.7 ± 20.4 mL, respectively) from baseline to 6 months follow-up. The amount of scar tissue was unchanged in the placebo group by 0.0 ± 1.6 g, p = 1.0 and in the ASC group with -0.3 ± 2.3 g, p = 0.540. There was no difference between the groups. There was a non-significant trend toward increased myocardial perfusion but no significant changes in functional parameters or amount of scar tissue in patients treated with ASCs compared with patients allocated into the placebo group.
- Published
- 2019
- Full Text
- View/download PDF
23. Recurrent Episodes of Pericardial Effusion as Isolated Manifestation of Tuberculosis: Case Report.
- Author
-
Westin O and Qayyum AA
- Subjects
- Adult, Antitubercular Agents therapeutic use, Humans, Male, Treatment Outcome, Pericardial Effusion diagnosis, Tuberculosis diagnosis
- Abstract
Background: Recurrent episodes of isolated pericardial effusion due to tuberculosis, leading to reduced Left Ventricle Ejection Fraction (LVEF), are uncommon., Methods: This is a case report of a previously healthy 32-years old male with tuberculous induced pericardial effusion as isolated manifestation. The only known exposure of tuberculosis was a brother with whom the patient did not have physical contact during the last year. The pericardial effusion repeatedly appeared after being drained a total of three times. Due to recurrent episodes of pericardial effusion, severe thickening of the pericardium, pericardial adherences and increasing affection on the heart, pericardiectomy was ultimately performed., Results: Biochemical examination, chest X-ray, computed tomography of thorax and abdomen and cytology report did not reveal any signs of malignancy, connective tissue disease or other infections including extra-pulmonary/pulmonary tuberculosis. However, the pericardial biopsy was Polymerase Chain Reaction positive (PCR) for tuberculosis DNA and showed granulomatous inflammation with necrosis. After 6 months anti-tuberculous therapy, biochemical parameters, LVEF and the clinical condition of the patient were normalized., Conclusion: Tuberculosis can be difficult to diagnose when it only manifests as pericardial effusion especially if the time for exposure is long before the appearance of symptoms and admission., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2019
- Full Text
- View/download PDF
24. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals.
- Author
-
Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, and Frikke-Schmidt R
- Subjects
- Adult, Aged, Aged, 80 and over, Cardiovascular Diseases blood, Cardiovascular Diseases epidemiology, Cardiovascular Diseases genetics, Cholesterol, HDL analysis, Cholesterol, HDL genetics, Cohort Studies, Cross-Sectional Studies, Denmark, Female, Humans, Male, Middle Aged, Myocardial Ischemia epidemiology, Phosphatidylcholine-Sterol O-Acyltransferase physiology, Polymorphism, Single Nucleotide physiology, Registries, Young Adult, Cholesterol, HDL blood, Mendelian Randomization Analysis, Myocardial Ischemia blood, Myocardial Ischemia genetics, Phosphatidylcholine-Sterol O-Acyltransferase genetics
- Abstract
Background: Epidemiologically, high-density lipoprotein (HDL) cholesterol levels associate inversely with risk of ischemic cardiovascular disease. Whether this is a causal relation is unclear., Methods: We studied 10,281 participants in the Copenhagen City Heart Study (CCHS) and 50,523 participants in the Copenhagen General Population Study (CGPS), of which 991 and 1,693 participants, respectively, had developed myocardial infarction (MI) by August 2010. Participants in the CCHS were genotyped for all six variants identified by resequencing lecithin-cholesterol acyltransferase in 380 individuals. One variant, S208T (rs4986970, allele frequency 4%), associated with HDL cholesterol levels in both the CCHS and the CGPS was used to study causality of HDL cholesterol using instrumental variable analysis., Results: Epidemiologically, in the CCHS, a 13% (0.21 mmol/liter) decrease in plasma HDL cholesterol levels was associated with an 18% increase in risk of MI. S208T associated with a 13% (0.21 mmol/liter) decrease in HDL cholesterol levels but not with increased risk of MI or other ischemic end points. The causal odds ratio for MI for a 50% reduction in plasma HDL cholesterol due to S208T genotype in both studies combined was 0.49 (0.11-2.16), whereas the hazard ratio for MI for a 50% reduction in plasma HDL cholesterol in the CCHS was 2.11 (1.70-2.62) (P(comparison) = 0.03)., Conclusion: Low plasma HDL cholesterol levels robustly associated with increased risk of MI but genetically decreased HDL cholesterol did not. This may suggest that low HDL cholesterol levels per se do not cause MI.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.